What Can You Expect at the UK & Western Europe’s Premier Tumour Modelling Forum in 2025?
As the European preclinical oncology market is projected to boom to $22.3 billion by 2033 led by the enhanced focus across targeted and next-generation immunotherapies, and the heightened regulatory push from the FDA and the EMA encouraging the use of non-animal methods including organoids and AI-based computational models in submissions, the need to understand which models are better at recapitulating the patient context has never been greater.
Built by biopharma for biopharma, the 14th Tumour Models Summit London returns this December to provide an update on tumour model advancements, and how to approach model selection and de-risk oncology drug development before entering the clinic.
Unmissable Event Highlights
Integrate organoid and humanised mouse model data with computational modelling to facilitate the creation of predictive in silico frameworks and enhance the predictability power of immunotherapy studies.
Develop predictive patient-derived resistance models to overcome resistance pathways and improve the clinical translatability of ADC therapies.
Ensure consistency and tackle donor-to-donor variability across mouse models through optimised humanisation strategies to support the large-scale discovery of T cell engagers.
Explore techniques to develop a spheroid co-culture model and characterise this co-culture model with CDX, PDX models and to empower the translation of pre|CISION®-peptide drug conjugates.
Employ robust assays and characterisation methods to optimise humanised mouse models to better understand efficacy and advance the translation of gamma-delta T cells to patients.
What’s New For 2025?
- 16+ New Case Studies from Drug Developers Across In Silico, Complex In Vitro & Humanised Mouse Models
- 83% of Speakers New to the Tumour Models Event
- 13 New Companies Represented on the Expert Speaker Faculty
- First-Ever Poster Competition at Tumour Models London! To celebrate the 14th anniversary of the meeting, we’re spotlighting innovation in tumour modelling during the Day Two morning break. The winner—crowned Industry Innovator of the Year—will be announced that afternoon.
Explore the Full Event Guide
- Free* to attend for biotech & pharma
- The longest-standing industry-focused meeting in the UK & western Europe dedicated to innovations & best practices in preclinical tumour modelling
- 18+ expert speakers delivering high-impact insights, practical experience & future-focused perspectives
- 16+ case studies on in vitro, complex in vitro, in vivo, in silico & more across diverse modalities & indications
- Exclusive networking & partnerships opportunities
Attending Companies Include
Explore the Agenda
Hear the latest preclinical and translational data on tumour modelling, and gain first-hand insight into innovations during our packed agenda of case studies, interactive roundtables, poster competition and dedicated panel discussions.
Partner With Us
Position yourself as the partner of choice amongst leading model developers and solution providers to ensure your brand is at the heart of biopharma deals and collaborations.
Join Oncology Industry Experts
Be part of the hottest conversations with like-minded attendees spanning a range of oncology modalities and indications, and make critical connections during our dedicated networking sessions.